This company has been marked as potentially delisted and may not be actively trading.

TC Biopharm (TCBP) Competitors

TCBP vs. HEPA, PRPH, VRAX, BPTSY, and BPTH

Should you be buying TC Biopharm stock or one of its competitors? The main competitors of TC Biopharm include Hepion Pharmaceuticals (HEPA), ProPhase Labs (PRPH), Virax Biolabs Group (VRAX), Biophytis (BPTSY), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical products" industry.

How does TC Biopharm compare to Hepion Pharmaceuticals?

TC Biopharm (NASDAQ:TCBP) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

: In the previous week, TC Biopharm's average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
TC Biopharm Neutral
Hepion Pharmaceuticals Neutral
: TC Biopharm's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
TC Biopharm N/A N/A N/A
Hepion Pharmaceuticals N/A -812.56% -207.31%
: TC Biopharm has higher revenue and earnings than Hepion Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TC Biopharm $4.76M 0.04 -$7.35M N/A N/A
Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A
: 16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: TC Biopharm has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Company	Overall Sentiment
TC Biopharm	Neutral
Hepion Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76M	0.04	-$7.35M	N/A	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Summary

TC Biopharm beats Hepion Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does TC Biopharm compare to ProPhase Labs?

TC Biopharm (NASDAQ:TCBP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

: In the previous week, TC Biopharm's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.
Company Overall Sentiment
TC Biopharm Neutral
ProPhase Labs Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TC Biopharm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
ProPhase Labs
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: TC Biopharm has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. TC Biopharm's return on equity of 0.00% beat ProPhase Labs' return on equity.
Company Net Margins Return on Equity Return on Assets
TC Biopharm N/A N/A N/A
ProPhase Labs -825.01% -482.05% -88.90%
: TC Biopharm has higher earnings, but lower revenue than ProPhase Labs.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TC Biopharm $4.76M 0.04 -$7.35M N/A N/A
ProPhase Labs $5.06M 0.18 -$53.36M -$3.90 N/A
: 16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: TC Biopharm has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

Company	Overall Sentiment
TC Biopharm	Neutral
ProPhase Labs	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
ProPhase Labs	-825.01%	-482.05%	-88.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76M	0.04	-$7.35M	N/A	N/A
ProPhase Labs	$5.06M	0.18	-$53.36M	-$3.90	N/A

Summary

TC Biopharm beats ProPhase Labs on 6 of the 10 factors compared between the two stocks.

How does TC Biopharm compare to Virax Biolabs Group?

TC Biopharm (NASDAQ:TCBP) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

: 16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: In the previous week, TC Biopharm's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.
Company Overall Sentiment
TC Biopharm Neutral
Virax Biolabs Group Neutral
: Virax Biolabs Group has a consensus target price of $1.00, indicating a potential upside of 721.69%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than TC Biopharm.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TC Biopharm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Virax Biolabs Group
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Company Net Margins Return on Equity Return on Assets
TC Biopharm N/A N/A N/A
Virax Biolabs Group N/A N/A N/A
: TC Biopharm has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
: Virax Biolabs Group has lower revenue, but higher earnings than TC Biopharm.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TC Biopharm $4.76M 0.04 -$7.35M N/A N/A
Virax Biolabs Group $10K 52.82 -$6.06M N/A N/A

Company	Overall Sentiment
TC Biopharm	Neutral
Virax Biolabs Group	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Virax Biolabs Group	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76M	0.04	-$7.35M	N/A	N/A
Virax Biolabs Group	$10K	52.82	-$6.06M	N/A	N/A

Summary

Virax Biolabs Group beats TC Biopharm on 7 of the 9 factors compared between the two stocks.

How does TC Biopharm compare to Biophytis?

TC Biopharm (NASDAQ:TCBP) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

: Company Net Margins Return on Equity Return on Assets
TC Biopharm N/A N/A N/A
Biophytis N/A N/A N/A
: TC Biopharm has higher revenue and earnings than Biophytis.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TC Biopharm $4.76M 0.04 -$7.35M N/A N/A
Biophytis N/A N/A -$18.43M N/A N/A
: 16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: In the previous week, TC Biopharm's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.
Company Overall Sentiment
TC Biopharm Neutral
Biophytis Neutral
: TC Biopharm has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76M	0.04	-$7.35M	N/A	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Company	Overall Sentiment
TC Biopharm	Neutral
Biophytis	Neutral

Summary

TC Biopharm beats Biophytis on 4 of the 5 factors compared between the two stocks.

How does TC Biopharm compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

: TC Biopharm's return on equity of 0.00% beat Bio-Path's return on equity.
Company Net Margins Return on Equity Return on Assets
Bio-Path N/A -2,842.40% -337.48%
TC Biopharm N/A N/A N/A
: 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 15.4% of TC Biopharm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: In the previous week, Bio-Path's average media sentiment score of 0.00 equaled TC Biopharm'saverage media sentiment score.
Company Overall Sentiment
Bio-Path Neutral
TC Biopharm Neutral
: TC Biopharm has higher revenue and earnings than Bio-Path.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Path N/A N/A -$16.08M -$1.06 N/A
TC Biopharm $4.76M 0.04 -$7.35M N/A N/A
: Bio-Path has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
TC Biopharm	N/A	N/A	N/A

Company	Overall Sentiment
Bio-Path	Neutral
TC Biopharm	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.06	N/A
TC Biopharm	$4.76M	0.04	-$7.35M	N/A	N/A

Summary

TC Biopharm beats Bio-Path on 7 of the 7 factors compared between the two stocks.

Get TC Biopharm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCBP vs. The Competition

Export

Metric	TC Biopharm	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$205K	$329.01M	$6.25B	$11.76B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	N/A	N/A	29.25	27.07
Price / Sales	0.04	189.48	504.69	73.43
Price / Cash	N/A	22.44	43.30	53.90
Price / Book	0.00	4.73	9.67	6.69
Net Income	-$7.35M	-$132.96M	$3.55B	$332.64M

TC Biopharm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCBP TC Biopharm	N/A	$0.50 flat	N/A	N/A	$205K	$4.76M	N/A	80
HEPA Hepion Pharmaceuticals	N/A	$0.07 +12.7%	N/A	-82.2%	$800K	N/A	N/A	20	Upcoming Earnings Gap Up High Trading Volume
PRPH ProPhase Labs	N/A	$0.13 -7.1%	N/A	-95.0%	$783K	$5.06M	N/A	130
VRAX Virax Biolabs Group	1.7631 of 5 stars	$0.13 -5.2%	$1.00 +647.4%	-88.0%	$610K	$10K	N/A	5	Gap Down
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCBP) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TC Biopharm (TCBP) Competitors

TCBP vs. HEPA, PRPH, VRAX, BPTSY, and BPTH

How does TC Biopharm compare to Hepion Pharmaceuticals?

Summary

How does TC Biopharm compare to ProPhase Labs?

Summary

How does TC Biopharm compare to Virax Biolabs Group?

Summary

How does TC Biopharm compare to Biophytis?

Summary

How does TC Biopharm compare to Bio-Path?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCBP vs. The Competition

TC Biopharm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TC Biopharm (TCBP) Competitors

TCBP vs. HEPA, PRPH, VRAX, BPTSY, and BPTH

How does TC Biopharm compare to Hepion Pharmaceuticals?

Summary

How does TC Biopharm compare to ProPhase Labs?

Summary

How does TC Biopharm compare to Virax Biolabs Group?

Summary

How does TC Biopharm compare to Biophytis?

Summary

How does TC Biopharm compare to Bio-Path?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCBP vs. The Competition

TC Biopharm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools